Skip to main content

Table 4 Outcomes of 14 patients with AE-ILD after chemotherapy

From: Protective effect of bevacizumab on chemotherapy-related acute exacerbation of interstitial lung disease in patients with advanced non-squamous non-small cell lung cancer

 

No.

Treatment line

Associated regimens

Onset of AE (days from chemotherapy)

Outcome

Survival time (days from onset of AE)

Non-Bev group

1

First

CDDP + PEM

79

Recover

125

2

First

CBDCA + PEM

110

Dead

87

3

First

CBDCA + PEM

5

Recovered

125

4

First

CBDCA + PEM

59

Dead

77

5

First

CBDCA + PEM

45

Dead

11

6

First

CBDCA + PEM

54

Recovered

626

7

First

CBDCA + PTX

87

Dead

36

8

Second

DOC

169

Recovered

276

9

Second

DOC

193

Recovered

522

10

Second

S-1

120

Dead

5

11

Second

DOC

426

Dead

4

12

Third

DOC

372

Dead

67

Bev group

13

Second

nab-PTX

156

Dead

34

14

Third

DOC

386

Dead

17

  1. AE acute exacerbation, Bev bevacizumab, CDDP cisplatin, PEM pemetrexed, CBDCA carboplatin, PTX paclitaxel, DOC docetaxel, nab-PTX nab-paclitaxel, VNR vinorelbine